---
layout: post
title: "MolecularPartners盘前涨超26%"
date: 2022-01-10 17:46:24 +0800
categories: emnews
tags: 东财滚动新闻
---
> MolecularPartners盘前涨超26%，公司和诺华制药表示已获得新冠候选治疗药物ensovibep2期研究的积极数据。

<p style="display:none;height:1px;overflow:hidden;"> </p><!-- EM_StockImg_Start --><p style="text-align:center;"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=105.MOLN&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" alt="K图 MOLN_0" data-code="K MOLN|105|7" data-code2="K MOLN|105|3|" style="border:#d1d1d1 1px solid;" width="578" height="276" border="0" /></p><!-- EM_StockImg_End --><p>MolecularPartners盘前涨超26%，公司和<span id="stock_106.NVS"><a href="http://quote.eastmoney.com/unify/r/106.NVS" class="keytip" data-code="106,NVS">诺华制药</a></span><span id="quote_106.NVS"></span>表示已获得新冠候选治疗药物ensovibep2期研究的积极数据。 <br /></p><p class="em_media">（文章来源：财联社）</p>

<http://stock.eastmoney.com/news/1611,202201102242276762.html>

[返回东财滚动新闻](//finews.withounder.com/emnews/)｜[返回首页](//finews.withounder.com/)